Search
Nafamostat
go.drugbank.com/drugs/DB12598InvestigationalThe use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.
Mandelic acid
go.drugbank.com/drugs/DB13218ApprovedMandelic acid is an approved aromatic, alpha hydroxy acid [L5458]. Mandelic acid is used as an ingredient in cosmetics and drug products applied topically.
SGN-15
go.drugbank.com/drugs/DB05818InvestigationalMonoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic.
Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15680ApprovedInvestigationalNeisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15681ApprovedInvestigationalDipivefrin
go.drugbank.com/drugs/DB00449ApprovedWithdrawnDipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
Edoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalTraditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for … By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots.
Cyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalAn anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties.
Daclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnRegardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by … withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an